IMPROVED DRUG ABSORPTION |
BETTER PATIENT COMPLIANCE

Improving Health

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technologies. 

Our Progressive Pipeline
Our Technology

Metabolic & Endocrine Solutions

LPCN 1144

—————

An oral prodrug of bioidentical testosterone  being developed for pre-cirrhotic NASH

Developed as a treatment of non-alcoholic steatohepatitis ("NASH").

LEARN MORE

TLANDO™

—————

An oral product of bioidentical testosterone being developed for testosterone replacement therapy.

Designed to help restore normal testosterone levels in males.

LEARN MORE

TLANDO XR

—————

A potentially once-daily oral prodrug of bioidentical testosterone in development for testosterone replacement therapy.

Uses Lip'ral technology to enhance solubility and improve systemic absorption.

LEARN MORE

LPCN 1148

—————

An oral prodrug of bioidentical testosterone being developed for the treatment of NASH cirrhosis. 

An oral prodrug of a bioidentical testosterone product candidate to treat NASH in Cirrhotic patients.

LEARN MORE

LPCN 1107

—————

Oral candidate of 17-alpha hydroxy-progesterone caproate being developed for the prevention of recurrent pre-term birth.

Prevents preterm birth in women with a prior history of at least one preterm birth.

LEARN MORE

Changing the Face of Oral Absorption Drugs

OUR PIONEERING LIP'RAL TECHNOLOGY ENABLES EFFICIENT ABSORPTION OF WATER INSOLUBLE DRUGS.

Our unique technology, coupled with our product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b)(2) regulatory pathway strategy. We are focused on metabolic and endocrine disorders such as:

  • Liver Disease (NASH)
  • Low Testosterone (Hypogonadism)
  • Recurrent Pre-Term Birth
See How It Works

Press Releases

Browse All Press & Events
Jan 14, 2021

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial and Appeal Board ("PTAB") of the United...

Jan 12, 2021

Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline results from its LiFT ("Liver Fat...

Browse All Press & Events

Corporate Presentations

Download Our Presentations

Innovative Pharmaceutical Products

ENHANCING HEALTH & IMPROVING PATIENT COMPLIANCE

See How We're Improving Health
Scroll to Top